Tim Chiang
Stock Analyst at Capital One
(1.07)
# 3,890
Out of 5,241 analysts
20
Total ratings
33.33%
Success rate
-5.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $0.8481 | +607.46% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $98.37 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $0.8183 | +8,454.32% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $17.82 | +146.91% | 2 | Jul 29, 2022 | |
| KALA KALA BIO | Maintains: Outperform | $15,000 → $10,000 | $2.53 | +395,156.92% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | $75 → $66 | $22.31 | +195.83% | 3 | May 5, 2021 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | $210 | $5.59 | +3,656.71% | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Neutral | n/a | $34.07 | - | 6 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | $33 | $15.85 | +108.20% | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $0.8481
Upside: +607.46%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $98.37
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $0.8183
Upside: +8,454.32%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $17.82
Upside: +146.91%
KALA BIO
Mar 30, 2022
Maintains: Outperform
Price Target: $15,000 → $10,000
Current: $2.53
Upside: +395,156.92%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: $75 → $66
Current: $22.31
Upside: +195.83%
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: $210
Current: $5.59
Upside: +3,656.71%
Teva Pharmaceutical Industries
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $34.07
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: $33
Current: $15.85
Upside: +108.20%